BACKGROUND: Uncertainty remains about possible cardiac adaptation to resistance training. Androgenic anabolic steroids (AAS) use plays a potential role and may have adverse cardiovascular effects. OBJECTIVE: To elucidate the effect of resistance training and of AAS-use on cardiac dimensions and function. PARTICIPANTS: Cardiac magnetic resonance (CMR) were performed in 156 male subjects aged 18-40 years: 52 non-athletes (maximum of 3 exercise hours/week), 52 strength-endurance (high dynamic-high static, HD-HS) athletes and 52 strength (low dynamic-high static, LD-HS) trained athletes (athletes ≥ 6 exercise hours/week). 28 LD-HS athletes denied and 24 admitted to AAS use for an average duration of 5 years (range 3 months-20 years). RESULTS: No significant differences were found between non-athletes and non-AAS-using LD-HS athletes. AAS-using LD-HS athletes had significantly larger LV and RV volumes and LV wall mass than non-AAS-using LD-HS athletes, but lower than HD-HS athletes. In comparison to all other groups AAS-using LD-HS athletes showed lower ejection fractions of both ventricles (LV/RV EF 51/48% versus 55-57/51-52%) and lower E/A ratios (LV/RV 1.5/1.2 versus 1.9-2.0/1.4-1.5) as an indirect measure of diastolic function. Linear regression models demonstrated a significant effect of AAS-use on LV EDV, LV EDM, systolic function and mitral valve E/A ratio (all ANOVA-tests p<0.05). CONCLUSIONS: Strength athletes who use AAS show significantly different cardiac dimensions and biventricular systolic dysfunction and impaired ventricular inflow as compared to non-athletes and non-AAS-using strength athletes. Increased ventricular volume and mass did not exceed that of strength-endurance athletes. These findings may help raise awareness of the consequences of AAS use.
BACKGROUND: Uncertainty remains about possible cardiac adaptation to resistance training. Androgenic anabolic steroids (AAS) use plays a potential role and may have adverse cardiovascular effects. OBJECTIVE: To elucidate the effect of resistance training and of AAS-use on cardiac dimensions and function. PARTICIPANTS: Cardiac magnetic resonance (CMR) were performed in 156 male subjects aged 18-40 years: 52 non-athletes (maximum of 3 exercise hours/week), 52 strength-endurance (high dynamic-high static, HD-HS) athletes and 52 strength (low dynamic-high static, LD-HS) trained athletes (athletes ≥ 6 exercise hours/week). 28 LD-HS athletes denied and 24 admitted to AAS use for an average duration of 5 years (range 3 months-20 years). RESULTS: No significant differences were found between non-athletes and non-AAS-using LD-HS athletes. AAS-using LD-HS athletes had significantly larger LV and RV volumes and LV wall mass than non-AAS-using LD-HS athletes, but lower than HD-HS athletes. In comparison to all other groups AAS-using LD-HS athletes showed lower ejection fractions of both ventricles (LV/RV EF 51/48% versus 55-57/51-52%) and lower E/A ratios (LV/RV 1.5/1.2 versus 1.9-2.0/1.4-1.5) as an indirect measure of diastolic function. Linear regression models demonstrated a significant effect of AAS-use on LV EDV, LV EDM, systolic function and mitral valve E/A ratio (all ANOVA-tests p<0.05). CONCLUSIONS: Strength athletes who use AAS show significantly different cardiac dimensions and biventricular systolic dysfunction and impaired ventricular inflow as compared to non-athletes and non-AAS-using strength athletes. Increased ventricular volume and mass did not exceed that of strength-endurance athletes. These findings may help raise awareness of the consequences of AAS use.
Authors: Josep M Alegret; Raúl Beltrán-Debón; Andre La Gerche; Luis Franco-Bonafonte; Francisco Rubio-Pérez; Nahum Calvo; Manuel Montero Journal: Eur J Appl Physiol Date: 2015-01-10 Impact factor: 3.078
Authors: Carlo De Innocentiis; Fabrizio Ricci; Mohammed Y Khanji; Nay Aung; Claudio Tana; Elvira Verrengia; Steffen E Petersen; Sabina Gallina Journal: Sports Med Date: 2018-11 Impact factor: 11.136
Authors: Carlo De Innocentiis; Fabrizio Ricci; Mohammed Y Khanji; Nay Aung; Claudio Tana; Elvira Verrengia; Steffen E Petersen; Sabina Gallina Journal: Sports Med Date: 2019-03 Impact factor: 11.136
Authors: Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin Journal: Endocr Rev Date: 2013-12-17 Impact factor: 19.871
Authors: Aaron L Baggish; Rory B Weiner; Gen Kanayama; James I Hudson; Michael T Lu; Udo Hoffmann; Harrison G Pope Journal: Circulation Date: 2017-05-23 Impact factor: 29.690
Authors: Stefan Baumann; Claude Jabbour; Aydin Huseynov; Martin Borggrefe; Dariusch Haghi; Theano Papavassiliu Journal: Asian J Sports Med Date: 2014-11-10